Catalent (CTLT)
(Delayed Data from NYSE)
$58.40 USD
-0.02 (-0.03%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $58.42 +0.02 (0.03%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth D Momentum F VGM
Catalent (CTLT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$62.36 | $63.50 | $56.00 | 6.74% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Catalent comes to $62.36. The forecasts range from a low of $56.00 to a high of $63.50. The average price target represents an increase of 6.74% from the last closing price of $58.42.
Analyst Price Targets (7 )
Broker Rating
Catalent currently has an average brokerage recommendation (ABR) of 2.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 2.60 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, two are Strong Buy, representing 20% of all recommendations. A month ago, Strong Buy represented 20%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 8 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.60 | 2.60 | 2.60 | 2.60 | 2.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/11/2024 | Not Identified | Not Identified | Hold | Hold |
6/28/2024 | Not Identified | Not Identified | Hold | Hold |
6/11/2024 | KeyBanc Capital Markets | Paul Knight | Hold | Hold |
4/4/2024 | Stephens | Jacob Johnson | Hold | Hold |
2/9/2024 | William Blair | Maxwell A Smock | Hold | Hold |
2/6/2024 | UBS | John N Sourbeer | Strong Buy | Hold |
2/5/2024 | Not Identified | Not Identified | Hold | Hold |
1/8/2024 | Robert W. Baird & Co. | Eric W Coldwell | Strong Buy | Strong Buy |
9/5/2023 | Argus Research Corp. | David A Toung | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.60 |
ABR (Last week) | 2.60 |
# of Recs in ABR | 10 |
Average Target Price | $62.36 |
LT Growth Rate | 29.20% |
Industry | Medical - Drugs |
Industry Rank by ABR | 100 of 252 |
Current Quarter EPS Est: | 0.46 |